GlassScriptPhysician profile
Yvette Reyes
NPI 1720179856
$1,647.64
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $355 · 2021: $652 · 2022: $205.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $550.31 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $422.24 | 2019-2021 | |
| Lundbeck LLC | $292.66 | 2019-2022 | |
| Abbvie INC. | $261.83 | 2021-2022 | |
| Indivior INC. | $68.52 | 2020-2021 | |
| Allergan, INC. | $38.17 | 2019-2020 | |
| Almatica Pharma LLC | $13.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yvette Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.